Vesper Bio initiates Phase Ib / IIa proof of concept study of VES001 in asymptomatic patients with gene mutations that cause frontotemporal dementia

Vesper Bio United Kingdom United States of America

Dosing of VES001 has commenced in patients with causal gene mutations for FTD(GRN), a type of frontotemporal dementia which is invariably fatalThis follows Vesper having received clinical trial authorisation from the Netherlands and the United Kingdom to initiate its Phase Ib/IIa 'SORT-IN-2' trialVES001 is a first-in-class, potentially disease-modifying, orally-dosed, brain-penetrant treatment for FTD(GRN), which elevates progranulin levels, a protein vital for neuronal health and for which FTD(GRN) patients are deficientVesper expects to complete dosing of all participants by mid-2025View original content:https://www.prnewswire.co.uk/news-releases/vesper-bio-initiates-phase-ibiia-proof-of-concept-study-of-ves001-in-asymptomatic-patients-with-gene-mutations-that-cause-frontotemporal-dementia-ftd-302344032.html

@ prnewswire.co.uk